Drreddy Rating
JPMORGAN ON DR REDDY'S : 17.05.2021
* JPMorgan maintains Neutral rating on Dr Reddy's. It says, co has limited near-term triggers
* MAINTAIN NEUTRAL TARGET: 4,850
* Believe Best For The Stock Is Behind Us
* After A Strong Rally Over Apr To Feb, Stock Has Lagged Nifty By 15%
* Core Biz In-line With Historical Average Despite Tractors At Cyclical High
JEFFERIES ON DR REDDY'S : 17.05.2021
* Maintain BUY, Target at Rs 5978/share
* Expects DRL to sell 250mn Sputnik V doses in the next 12 months in India
* Company plans to launch gVasecpa in the next two months with regular supplies
* We change our FY22/23 estimates by -5%/0%
MS ON DR REDDY'S : 17.05.2021
* MS has an Overweight call on Dr Reddy's. Kuvan, Vascepa, Revlimid generic & Sputnik are near-to-mid-term growth drivers
* MAINTAIN OVERWEIGHT TARGET: 5,859
* Seeing Sustained Growth Across Most Of Its Key Markets
* Tight Cost Control & Productivity Gains Are Improving Margin
* Kuvan, Vascepa, Revlimid, Sputnik Are Near-to-mid term Growth Drivers
GOLDMAN SACHS ON DR REDDY'S : 17.05.2021
* Goldman Sachs has a Neutral call on Dr Reddy's with intensity of US mkt pricing pressure & US FDA GMP compliance being key risks
* MAINTAIN NEUTRAL TARGET: 5,250
* Q4 In-line; Focus Is On Sputnik V Ramp-up
* Revise Our FY22-24 EBITDA By Up To 4% On Average
* Litigation Around Key Pipeline Opportunities A Key Risk
* Intensity Of US Mkt Pricing Pressure, US FDA GMP Compliance Key Risks
